Due to the aforementioned special relevance of PD-L1 in antibody-based anti-tumor immunotherapies, particularly its presence as a membrane-bound or secreted protein, the PD-L1 sequence was analyzed for the presence of SRSF2 recognition sites. The gene discussed is CD274; the disease is neoplasm.